Abstract:Background and Objectives: Myopia is the most widespread ocular disorder globally and its prevalence has been increasing over the past decades. Atropine eye drops stand out as the only pharmacological intervention used in clinical practice to control myopia progression. The aim of this study was to explore the effect of 0.01% atropine eye drops on myopia progression. Patients and Methods: Healthy children aged 6-12 years with cycloplegic spherical equivalent (SE) from -0.5 D to -5.0 D and astigmatism ≤1.5 D were included. Myopia progression was assessed by changes in SE and axial length (AL) over 1 year and SE changes 1 year before the study enrollment and during the 1-year follow-up. Adverse events were evaluated based on complaints reported by either parents or the children themselves during follow-up visits. Results: The analysis involved 55 patients in the 0.01% atropine eye drops group and 66 in the control group. After the 1-year follow-up, the change in SE was -0.50 (-2.25-0.50) D in the control group compared to -0.50 (-1.50-0.50) D in the 0.01% atropine group (p = 0.935); AL change was 0.31 (0.18) mm in the control group and 0.29 (0.18) mm in the 0.01% atropine group (p = 0.480). The change in SE was -0.68 (-2.0--0.25) D/year before the study and remained similar -0.50 (-2.25-0.25) D over the 1-year follow-up in the control group (p = 0.111); SE change was reduced from -1.01 (-2.0--0.25) D/year before the study to -0.50 (-1.5-0.5) D over the 1-year follow-up in the 0.01% atropine group (p < 0.001). In the 0.01% atropine group, ten (16.4%) children experienced mild adverse events, including blurred near vision, ocular discomfort, photophobia, dry eyes, and anisocoria. Conclusions: Compared to the control group, the administration of 0.01% atropine eye drops demonstrated no significant effect on changes in SE and AL over a 1-year follow-up. However, children in the 0.01% atropine group initially experienced higher myopia progression, which decreased with treatment over the course of 1 year. Future studies should explore the long-term effects, rebound effects, potential genetic associations, and efficacy of higher doses of atropine in managing myopia progression.

Nutrition of Australian Aboriginal infants and children

[Atropine use for progressive myopia in children and adolescents]

Eldridge Campbell; 1901-1956.

DsbA of Pseudomonas aeruginosa Is Essential for Multiple Virulence Factors

Body temperature regulation and outcome after cardiac arrest and therapeutic hypothermia.

Myopia Control in Caucasian Children with 0.01% Atropine Eye Drops: 1-Year Follow-Up Study

Effective Decrease in Myopia Progression With Two Mechanisms of Management

The genetics of hereditary disorders of blood coagulation.

Atropine Slows Myopia Progression More in Asian Than White Children by Meta-analysis

Strength and lactone formation of gluconic acid.

Efficacy and Safety of 1% Atropine on Retardation of Moderate Myopia Progression in Chinese School Children

Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients

Efficacy and Safety of Low Dose Atropine 0.01% in Slowing of Progression of Myopia

Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis

Real-world outcomes of low-dose atropine therapy on myopia progression in an Australian cohort during the COVID-19 pandemic

Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia – Atropine for the Treatment of Myopia (WA‐ATOM) study

Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population

Effects of Atropine 0.01% on Refractive Errors in Children with Myopia.

Five-year results of atropine 0.01% efficacy in the myopia control in a European population

Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression

A One-Year Prospective Clinical Study